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The osteoarthritis (OA) research community has long-standing
experience with studies assessing structure-modifying therapeutic
efﬁcacy,which is commonly deﬁned as slowingof joint space narrow-
ing (JSN)onanterior-posterior radiographs1. Paramount for longitudi-
nal radiologic evaluation of radiographs in efﬁcacy studies is
optimized image acquisition in a reliable fashion commonly using
ﬁxed-ﬂexionprotocols orﬂuoroscopy to conﬁrmsatisfactoryanatom-
ical positioning of the medial tibial plateau prior to acquisition of
the radiograph in order to guarantee comparability between time
points2,3. Eligibility is usually based on semi-quantitative assessment
according to the KellgreneLawrence or OARSI grading schemes4,5.
Recently monoclonal antibodies that bind and inhibit nerve
growth factor (a-NGF) have been introduced for treatment of OA
symptoms and have shown good analgesic efﬁcacy and improve-
ment in function in patients with OA6,7. However, despite initial
promising data a-NGF trials in OA had been suspended due to con-
cerns over accelerated rates of OA progression and other complica-
tions such as subchondral insufﬁciency fracture and osteonecrosis.
Since a-NGF therapies offer potential as the ﬁrst new class of anal-
gesics for many years, future studies assessing a-NGF compounds
will have to include stringent eligibility criteria and will require a
rigorous safety monitoring. While disease-modifying structural ef-
fects are not expected in a-NGF treatment, imaging plays a crucial
role in clinical trials to deﬁne eligibility of potential participants
with focus on exclusion criteria and to monitor safety during the
course of these studies to identify either subjects at risk for fast
OA progression prior inclusion or withdraw subjects from study
early to avoid adverse events such as rapid progressive OA.
The role of radiologic assessment differs in efﬁcacy and a-NGF
studies. While in efﬁcacy studies image acquisition and evaluation
is optimized for sensitivity to detect minor changes between
treated and non-treated subjects over time, in a-NGF studies the
focus is on early detection of imaging ﬁndings that either put a sub-
ject at increased risk for an adverse outcome (eligibility) or may
result in withdrawal from treatment (safety). These include but
are not limited to rapid progressive OA and osteonecrosis.
With a-NGF programs are likely to resume in the near future
we felt there is an urgent need to inform the community about
potential imaging ﬁndings that may be relevant for eligibility
and safety in a-NGF studies and are very grateful to the Editor
in Chief and the Editorial Board of Osteoarthritis and Cartilage to
have invited us as Guest Editors for this special supplement. The
atlases were speciﬁcally developed to illustrate in an exemplaryhttp://dx.doi.org/10.1016/j.joca.2014.08.014
1063-4584/© 2014 Osteoarthritis Research Society International. Published by Elsevier Lfashion the imaging ﬁndings that may be encountered during a-
NGF trials and/or in patients being treated with a-NGF compounds
after possible approval of these drugs by the regulatory author-
ities. We felt it important to give the community, which is largely
composed of non-radiologists or imaging experts, an opportunity
to have access to such important information. We hope that these
atlases will beneﬁt anyone who is involved in the development,
application or assessment of a-NGF compounds. This may be the
pharmaceutical industry, contract research organizations (CROs),
imaging experts involved in reading and assessment, treating phy-
sicians and potentially even patients. We wish to point out that
the pharmaceutical industry was not involved in the development
of the presented manuscripts.
Dr Colin Miller who has long-standing experience with both,
OA efﬁcacy studies and a-NGF clinical trials gives an introduction
and overview on past a-NGF clinical trials and particularly reviews
the role of imaging in the context of a-NGF studies. Dr Thomas
Schnitzer, who has been involved in a-NGF programs for an
extended period of time systematically reviews together with
Dr Julia Marks the efﬁcacy and general safety of antibodies to
NGF in the treatment of OA of the hip or knee. Dr Marc Hochberg
who has been involved closely in the adjudication of adverse
events in the tanezumab program for several years, gives a
detailed overview of serious joint-related adverse events in
a-NGF trials. Finally, three imaging atlas parts focusing on all the
major articulating joints that were affected in the prior studies,
i.e., the knee, hip and shoulder will be presented by a team of
four experienced musculoskeletal radiologists and an additional
imaging expert covering relevant imaging ﬁndings for eligibility
and on-study safety.
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